Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis

Diabetes Research and Clinical Practice

Volumn 129, Issue , 2017, Pages 213-223

  Wang, Wen ^a   Gao, Yun ^a   Chen, Dawei ^a   Wang, Chun ^a   Feng, Xiaobing ^a   Ran, Xingwu ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

DPP 4; GLP 1; Incretin; Type 1 diabetes

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; ANTIDIABETIC AGENT; INCRETIN;

ACUTE CORONARY SYNDROME; ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; COHORT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; META ANALYSIS; MULTICENTER STUDY (TOPIC); NAUSEA; OBSERVATIONAL STUDY; PANCREATITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; VOMITING; ADULT; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; RISK; YOUNG ADULT;

ADULT; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; MIDDLE AGED; RISK; YOUNG ADULT;

EID: 85019621652     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.05.007     Document Type: Article

References (45)

1. Daneman, D., Type 1 diabetes. Lancet 367:9513 (2006), 847–858.
2. Lauria, A., Barker, A., Schloot, N., et al. BMI is an important driver of beta-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol 172:2 (2015), 107–113.
3. Wilkin, T.J., The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond) 33:7 (2009), 716–726.
4. Varanasi, A., Bellini, N., Rawal, D., et al. Liraglutide as additional treatment for type 1 diabetes. Eur J Endocrinol 165:1 (2011), 77–84.
5. Greenbaum, C.J., Prigeon, R.L., D'Alessio, D.A., Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 51:4 (2002), 951–957.
6. Frandsen, C.S., Dejgaard, T.F., Madsbad, S., Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. Lancet Diabetes Endocrinol 4:9 (2016), 766–780.
7. Cryer, P.E., Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45:7 (2002), 937–948.
8. Libman, I.M., Miller, K.M., DiMeglio, L.A., et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 314:21 (2015), 2241–2250.
9. Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:9 (2015), 1687–1693.
10. Jonas, D., Van Scoyoc, E., Gerrald, K., et al. Drug class review: newer diabetes medications, TZDs, and combinations: final original report. 2011, Oregon Health & Science University, Portland (OR).
11. Garg, S.K., Moser, E.G., Bode, B.W., et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: Investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocrine Pract 19:1 (2013), 19–28.
12. Campbell, J.E., Drucker, D.J., Islet α cells and glucagon–critical regulators of energy homeostasis. Nat Rev Endocrinol 11:6 (2015), 329–338.
13. Ahren, B., Hirsch, I.B., Pieber, T.R., et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care 39:10 (2016), 1693–1701.
14. Mathieu, C., Zinman, B., Hemmingsson, J.U., et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 39:10 (2016), 1702–1710.
15. Hari Kumar, K.V., Shaikh, A., Prusty, P., Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. Diabetes Res Clin Pract 100:2 (2013), e55–e58.
16. Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N., Hirshberg, B., Saxagliptin improves glycaemic control and C-peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes Metab Res Rev 32:3 (2016), 289–296.
17. Johansen, O.E., Boehm, B.O., Grill, V., et al. C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study. Diabetes Care 37:1 (2014), e11–e12.
18. Zhao, Y., Yang, L., Xiang, Y., et al. Dipeptidyl peptidase 4 inhibitor sitagliptin maintains beta-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study. J Clin Endocrinol Metab 99:5 (2014), E876–E880.
19. Frandsen, C.S., Dejgaard, T.F., Holst, J.J., Andersen, H.U., Thorsteinsson, B., Madsbad, S., Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo- controlled, double-blind parallel study. Diabetes Care 38:12 (2015), 2250–2257.
20. Griffin, K.J., Thompson, P.A., Gottschalk, M., Kyllo, J.H., Rabinovitch, A., Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2:9 (2014), 710–718.
21. Dejgaard, T.F., Frandsen, C.S., Hansen, T.S., et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 4:3 (2016), 221–232.
22. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
23. Guyatt GH, Busse JW. Tool to assess risk of bias in randomized controlled trials. < https://distillercer.com/resources/>.
24. Wells GA, Shea B, O'Connell D, et al. University of Ottawa. The Newcastle Ottawa Scale (NOS) for assessing the quality of non randomised studies in Meta analyses; 2011. < http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>.
25. Guyatt GH, Busse JW. Tool to assess risk of bias in cohort studies. < https://distillercer.com/resources/>.
26. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21:11 (2002), 1539–1558.
27. Kuhadiya, N.D., Dhindsa, S., Ghanim, H., et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care 39:6 (2016), 1027–1035.
28. Kielgast, U., Krarup, T., Holst, J.J., Madsbad, S., Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:7 (2011), 1463–1468.
29. Deacon, C.F., Mannucci, E., Ahren, B., Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 14:8 (2012), 762–767.
30. Karagiannis, T., Paschos, P., Paletas, K., Matthews, D.R., Tsapas, A., Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 344, 2012, e1369.
31. Vilsboll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
32. Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:2 (2007), 194–206.
33. Kim, Y.G., Min, S.H., Hahn, S., Oh, T.J., Park, K.S., Cho, Y.M., Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 116 (2016), 86–95.
34. Liu, S.C., Tu, Y.K., Chien, M.N., Chien, K.L., Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 14:9 (2012), 810–820.
35. Eng, C., Kramer, C.K., Zinman, B., Retnakaran, R., Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384 (2014), 2228–2234.
36. Chen, C., Yu, Q., Zhang, S., Yang, P., Wang, C.Y., Assessing the efficacy and safety of combined DPP-4 inhibitor and insulin treatment in patients with type 2 diabetes: a meta-analysis. Int J Clin Exp Pathol 8:11 (2015), 14141–14150.
37. Maruthur, N.M., Tseng, E., Hutfless, S., et al. Diabetes medications as monotherapy or metformin-based combination therapy for Type 2 diabetes: a systematic review and meta-analysis. Ann Int Med 164:11 (2016), 740–751.
38. Li, L., Shen, J., Bala, M.M., et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ, 348, 2014, g2366.
39. Abbas, A.S., Dehbi, H.M., Ray, K.K., Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: a meta-analysis of randomized controlled cardiovascular outcome trials. Diabetes Obes Metab 18:3 (2016), 295–299.
40. Li, L., Li, S., Deng, K., et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610.
41. Seshasai, S.R., Bennett, R.L., Petrie, J.R., et al. Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. Diabetes Obes Metab 17:5 (2015), 505–510.
42. Johansen, O.E., Neubacher, D., von Eynatten, M., Patel, S., Woerle, H.J., Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol, 11, 2012, 3.
43. Mannucci, E., Monami, M., Cardiovascular safety of incretin-based therapies in type 2 diabetes: systematic review of integrated analyses and randomized controlled trials. Adv Ther 34:1 (2017), 1–40.
44. Wang, T., Wang, F., Zhou, J., Tang, H., Giovenale, S., Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes Metab Res Rev 32:8 (2016), 843–857.
45. Higgins J, Green S. The Cochrane Collaboration.Cochrane handbook for systematic reviews of interventions version 5.1.0; 2011. < http://handbook.cochrane.org/>.